If a variant has more than one submission, it may be counted in more than one significance column. If this is the
case, the total number of variants will be less than the sum of the other cells.
Gene and significance breakdown #
Total genes and gene combinations: 315
Gene or gene combination |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
total |
APC
|
1237
|
82
|
159
|
257
|
1844
|
3579
|
ATM
|
739
|
161
|
1
|
564
|
1207
|
2672
|
ATM, C11orf65
|
409
|
152
|
0 |
366
|
631
|
1558
|
MSH6
|
876
|
103
|
99
|
66
|
68
|
1212
|
MSH2
|
698
|
185
|
59
|
69
|
44
|
1055
|
PALB2
|
676
|
75
|
58
|
61
|
68
|
938
|
MLH1
|
628
|
149
|
30
|
56
|
41
|
904
|
BRIP1
|
394
|
70
|
100
|
11
|
26
|
601
|
CHEK2
|
312
|
129
|
69
|
31
|
14
|
555
|
PMS2
|
298
|
103
|
70
|
18
|
24
|
513
|
TP53
|
156
|
253
|
40
|
5
|
13
|
467
|
PTEN
|
297
|
117
|
12
|
10
|
7
|
443
|
CDH1
|
211
|
71
|
87
|
15
|
19
|
403
|
BARD1
|
280
|
58
|
17
|
25
|
12
|
392
|
AXIN2
|
38
|
4
|
0 |
34
|
240
|
316
|
BRCA2
|
190
|
9
|
0 |
66
|
13
|
278
|
MSH3
|
191
|
52
|
0 |
2
|
0 |
245
|
DNAH5
|
1
|
182
|
0 |
0 |
0 |
183
|
NEB
|
3
|
164
|
1
|
0 |
0 |
168
|
RAD51C
|
80
|
53
|
13
|
12
|
9
|
167
|
RAD51D, RAD51L3-RFFL
|
75
|
47
|
22
|
10
|
9
|
163
|
LAMA2
|
1
|
157
|
3
|
0 |
0 |
161
|
BRCA1
|
69
|
21
|
2
|
45
|
11
|
148
|
SDHA
|
65
|
27
|
30
|
9
|
2
|
133
|
STK11
|
29
|
11
|
42
|
20
|
26
|
128
|
CFTR
|
59
|
66
|
0 |
0 |
0 |
125
|
PKHD1
|
6
|
109
|
2
|
0 |
0 |
117
|
BMPR1A
|
56
|
14
|
18
|
11
|
6
|
105
|
ZFYVE26
|
0 |
99
|
1
|
0 |
0 |
100
|
DYSF
|
2
|
92
|
3
|
0 |
0 |
97
|
MYO7A
|
1
|
85
|
7
|
0 |
0 |
93
|
USH2A
|
7
|
62
|
15
|
0 |
0 |
84
|
COL4A3, MFF-DT
|
0 |
78
|
3
|
0 |
0 |
81
|
SMAD4
|
37
|
11
|
15
|
8
|
8
|
79
|
NTHL1
|
65
|
12
|
0 |
1
|
0 |
78
|
RET
|
20
|
5
|
30
|
14
|
9
|
78
|
AGL
|
2
|
73
|
0 |
0 |
0 |
75
|
COL4A4
|
1
|
72
|
2
|
0 |
0 |
75
|
FLCN
|
53
|
13
|
0 |
4
|
3
|
73
|
COL4A5
|
0 |
70
|
0 |
0 |
0 |
70
|
CPS1
|
0 |
64
|
2
|
0 |
0 |
66
|
GNPTAB
|
2
|
64
|
0 |
0 |
0 |
66
|
FH
|
34
|
30
|
0 |
1
|
0 |
65
|
ATP7B
|
8
|
49
|
7
|
0 |
0 |
64
|
ATP7A
|
0 |
61
|
0 |
0 |
0 |
61
|
DMD
|
0 |
61
|
0 |
0 |
0 |
61
|
CTNNA1
|
51
|
7
|
0 |
2
|
0 |
60
|
GLDC
|
1
|
56
|
3
|
0 |
0 |
60
|
NPC1
|
3
|
54
|
3
|
0 |
0 |
60
|
BAP1
|
42
|
10
|
0 |
4
|
1
|
57
|
ALMS1
|
0 |
56
|
0 |
0 |
0 |
56
|
LAMB3
|
4
|
52
|
0 |
0 |
0 |
56
|
LRPPRC
|
0 |
54
|
0 |
0 |
0 |
54
|
ERCC6
|
0 |
49
|
0 |
0 |
0 |
49
|
ELP1
|
1
|
47
|
0 |
0 |
0 |
48
|
MAN2B1
|
2
|
46
|
0 |
0 |
0 |
48
|
MTTP
|
0 |
48
|
0 |
0 |
0 |
48
|
PCDH15
|
1
|
41
|
5
|
0 |
0 |
47
|
SDHB
|
27
|
14
|
5
|
0 |
1
|
47
|
CDKN2A
|
5
|
10
|
16
|
5
|
7
|
43
|
EVC
|
0 |
42
|
0 |
0 |
0 |
42
|
LAMC2
|
1
|
41
|
0 |
0 |
0 |
42
|
SLC26A4
|
11
|
22
|
9
|
0 |
0 |
42
|
ABCC8
|
2
|
32
|
7
|
0 |
0 |
41
|
PAH
|
19
|
22
|
0 |
0 |
0 |
41
|
HEXA
|
8
|
30
|
2
|
0 |
0 |
40
|
HLCS
|
0 |
39
|
1
|
0 |
0 |
40
|
PEX1
|
2
|
37
|
1
|
0 |
0 |
40
|
EVC2
|
1
|
37
|
1
|
0 |
0 |
39
|
MEN1
|
17
|
6
|
6
|
5
|
4
|
38
|
PC
|
0 |
38
|
0 |
0 |
0 |
38
|
FANCA
|
1
|
34
|
1
|
0 |
0 |
36
|
BBS2
|
2
|
30
|
3
|
0 |
0 |
35
|
NEB, RIF1
|
0 |
35
|
0 |
0 |
0 |
35
|
VPS13B
|
2
|
29
|
2
|
0 |
0 |
33
|
GAA
|
5
|
24
|
3
|
0 |
0 |
32
|
MPL
|
1
|
31
|
0 |
0 |
0 |
32
|
SLC12A6
|
2
|
30
|
0 |
0 |
0 |
32
|
NPHS1
|
2
|
26
|
3
|
0 |
0 |
31
|
TSC2
|
7
|
6
|
0 |
9
|
9
|
31
|
GALT
|
5
|
24
|
1
|
0 |
0 |
30
|
ACADVL
|
3
|
16
|
10
|
0 |
0 |
29
|
HPS3
|
1
|
28
|
0 |
0 |
0 |
29
|
HSD17B4
|
0 |
26
|
2
|
0 |
0 |
28
|
MMUT
|
0 |
27
|
1
|
0 |
0 |
28
|
SDHC
|
14
|
9
|
4
|
1
|
0 |
28
|
SACS
|
2
|
24
|
1
|
0 |
0 |
27
|
TSC1
|
14
|
7
|
0 |
4
|
2
|
27
|
HEXB
|
1
|
25
|
0 |
0 |
0 |
26
|
ASL
|
4
|
20
|
1
|
0 |
0 |
25
|
HGSNAT
|
3
|
19
|
3
|
0 |
0 |
25
|
DHCR7
|
7
|
17
|
0 |
0 |
0 |
24
|
LOXHD1
|
0 |
23
|
1
|
0 |
0 |
24
|
TGM1
|
3
|
19
|
2
|
0 |
0 |
24
|
IDUA
|
2
|
21
|
0 |
0 |
0 |
23
|
MTM1
|
0 |
23
|
0 |
0 |
0 |
23
|
PFKM
|
1
|
22
|
0 |
0 |
0 |
23
|
PMM2
|
8
|
14
|
1
|
0 |
0 |
23
|
ADAMTS2
|
1
|
21
|
0 |
0 |
0 |
22
|
CBS
|
4
|
16
|
2
|
0 |
0 |
22
|
GJB2
|
15
|
1
|
6
|
0 |
0 |
22
|
CAPN3
|
3
|
16
|
2
|
0 |
0 |
21
|
CYP27A1
|
4
|
17
|
0 |
0 |
0 |
21
|
DBT
|
1
|
20
|
0 |
0 |
0 |
21
|
GALC
|
4
|
16
|
1
|
0 |
0 |
21
|
HBB, LOC106099062, LOC107133510
|
16
|
5
|
0 |
0 |
0 |
21
|
AGXT
|
3
|
16
|
1
|
0 |
0 |
20
|
DLD
|
2
|
18
|
0 |
0 |
0 |
20
|
GNE
|
5
|
15
|
0 |
0 |
0 |
20
|
LOC129390903, RAD51C
|
13
|
4
|
0 |
3
|
0 |
20
|
PCCA
|
0 |
19
|
1
|
0 |
0 |
20
|
PEX6
|
0 |
20
|
0 |
0 |
0 |
20
|
MKS1
|
1
|
18
|
0 |
0 |
0 |
19
|
POLD1
|
0 |
3
|
7
|
8
|
1
|
19
|
POLE
|
0 |
0 |
15
|
3
|
1
|
19
|
AIRE
|
3
|
15
|
0 |
0 |
0 |
18
|
ALDH3A2
|
1
|
17
|
0 |
0 |
0 |
18
|
NBN
|
0 |
18
|
0 |
0 |
0 |
18
|
TPP1
|
3
|
15
|
0 |
0 |
0 |
18
|
USH1C
|
2
|
14
|
2
|
0 |
0 |
18
|
BCKDHA
|
2
|
14
|
1
|
0 |
0 |
17
|
BCKDHB
|
0 |
16
|
1
|
0 |
0 |
17
|
BRCA1, LOC126862571
|
9
|
0 |
0 |
7
|
1
|
17
|
GALK1
|
0 |
16
|
1
|
0 |
0 |
17
|
ALPL
|
4
|
11
|
1
|
0 |
0 |
16
|
CNGB3
|
0 |
14
|
2
|
0 |
0 |
16
|
CPT1A
|
1
|
15
|
0 |
0 |
0 |
16
|
F11
|
0 |
14
|
2
|
0 |
0 |
16
|
LIPA
|
2
|
14
|
0 |
0 |
0 |
16
|
MLC1
|
1
|
15
|
0 |
0 |
0 |
16
|
POMGNT1, TSPAN1
|
3
|
12
|
1
|
0 |
0 |
16
|
STAR
|
1
|
15
|
0 |
0 |
0 |
16
|
ACADM
|
3
|
12
|
0 |
0 |
0 |
15
|
ADA
|
1
|
14
|
0 |
0 |
0 |
15
|
ALDOB
|
3
|
9
|
3
|
0 |
0 |
15
|
ALG6
|
0 |
14
|
1
|
0 |
0 |
15
|
CYP11B1, LOC106799833
|
0 |
14
|
1
|
0 |
0 |
15
|
GLB1
|
0 |
15
|
0 |
0 |
0 |
15
|
LOC107303340, VHL
|
10
|
4
|
0 |
1
|
0 |
15
|
MUTYH
|
7
|
7
|
0 |
1
|
0 |
15
|
PEX7
|
2
|
13
|
0 |
0 |
0 |
15
|
VHL
|
10
|
5
|
0 |
0 |
0 |
15
|
ARSA
|
6
|
8
|
0 |
0 |
0 |
14
|
CTSK
|
0 |
14
|
0 |
0 |
0 |
14
|
FAH
|
5
|
9
|
0 |
0 |
0 |
14
|
HADHA
|
0 |
14
|
0 |
0 |
0 |
14
|
IVD
|
1
|
12
|
1
|
0 |
0 |
14
|
SMPD1
|
2
|
8
|
4
|
0 |
0 |
14
|
TH
|
1
|
13
|
0 |
0 |
0 |
14
|
FKTN
|
1
|
12
|
0 |
0 |
0 |
13
|
GATAD1, PEX1
|
0 |
13
|
0 |
0 |
0 |
13
|
LOC130062899, STK11
|
3
|
0 |
4
|
1
|
5
|
13
|
NPC2
|
0 |
13
|
0 |
0 |
0 |
13
|
SLC17A5
|
1
|
12
|
0 |
0 |
0 |
13
|
SLC22A5
|
2
|
9
|
2
|
0 |
0 |
13
|
BBS1, ZDHHC24
|
1
|
10
|
1
|
0 |
0 |
12
|
CFTR, LOC111674475
|
9
|
3
|
0 |
0 |
0 |
12
|
ERCC8
|
1
|
11
|
0 |
0 |
0 |
12
|
GRHPR
|
1
|
11
|
0 |
0 |
0 |
12
|
LOC122152296, USH2A
|
0 |
10
|
2
|
0 |
0 |
12
|
TCIRG1
|
1
|
10
|
1
|
0 |
0 |
12
|
AOPEP, FANCC
|
1
|
10
|
0 |
0 |
0 |
11
|
ASS1
|
1
|
9
|
1
|
0 |
0 |
11
|
BCS1L
|
2
|
7
|
2
|
0 |
0 |
11
|
G6PC1
|
7
|
4
|
0 |
0 |
0 |
11
|
KIRREL2, NPHS1
|
1
|
8
|
2
|
0 |
0 |
11
|
MCOLN1
|
1
|
10
|
0 |
0 |
0 |
11
|
MMAA
|
1
|
10
|
0 |
0 |
0 |
11
|
PCCB
|
1
|
10
|
0 |
0 |
0 |
11
|
ACADS
|
1
|
9
|
0 |
0 |
0 |
10
|
ARG1, MED23
|
1
|
9
|
0 |
0 |
0 |
10
|
ASPA, SPATA22
|
4
|
6
|
0 |
0 |
0 |
10
|
BTD
|
6
|
2
|
2
|
0 |
0 |
10
|
CFTR, LOC111674472
|
7
|
3
|
0 |
0 |
0 |
10
|
CLN3
|
0 |
7
|
3
|
0 |
0 |
10
|
DHFR, MSH3
|
8
|
0 |
0 |
0 |
2
|
10
|
FANCC
|
2
|
8
|
0 |
0 |
0 |
10
|
GCDH
|
2
|
7
|
1
|
0 |
0 |
10
|
LOC129933707, MSH6
|
2
|
4
|
1
|
1
|
2
|
10
|
SGSH
|
1
|
8
|
1
|
0 |
0 |
10
|
GAREM2, HADHA
|
1
|
8
|
0 |
0 |
0 |
9
|
HGD
|
0 |
9
|
0 |
0 |
0 |
9
|
HMGCL
|
0 |
7
|
2
|
0 |
0 |
9
|
NPHS2
|
2
|
6
|
1
|
0 |
0 |
9
|
SGCA
|
1
|
7
|
1
|
0 |
0 |
9
|
ERCC6, PGBD3
|
0 |
8
|
0 |
0 |
0 |
8
|
LOC126807437, MSH3
|
8
|
0 |
0 |
0 |
0 |
8
|
LOC126859690, PKHD1
|
1
|
7
|
0 |
0 |
0 |
8
|
SDHD
|
7
|
1
|
0 |
0 |
0 |
8
|
ABCD1
|
0 |
6
|
1
|
0 |
0 |
7
|
CHM
|
0 |
7
|
0 |
0 |
0 |
7
|
CLN6
|
1
|
6
|
0 |
0 |
0 |
7
|
CTNS
|
1
|
6
|
0 |
0 |
0 |
7
|
DNAH5, LOC126807318
|
0 |
7
|
0 |
0 |
0 |
7
|
GBA1, LOC106627981
|
4
|
3
|
0 |
0 |
0 |
7
|
GNPTG
|
0 |
6
|
1
|
0 |
0 |
7
|
MMACHC
|
1
|
5
|
1
|
0 |
0 |
7
|
NAGLU
|
0 |
6
|
1
|
0 |
0 |
7
|
OTC
|
0 |
7
|
0 |
0 |
0 |
7
|
POMGNT1
|
0 |
7
|
0 |
0 |
0 |
7
|
TAT
|
0 |
7
|
0 |
0 |
0 |
7
|
BBS1
|
0 |
5
|
1
|
0 |
0 |
6
|
CDK4
|
0 |
0 |
2
|
1
|
3
|
6
|
CP, HPS3
|
0 |
6
|
0 |
0 |
0 |
6
|
CPT2
|
3
|
1
|
2
|
0 |
0 |
6
|
CYP21A2, LOC106780800
|
6
|
0 |
0 |
0 |
0 |
6
|
EVC, LOC129992144
|
0 |
6
|
0 |
0 |
0 |
6
|
EVC2, LOC126806961
|
0 |
6
|
0 |
0 |
0 |
6
|
IDS, LOC106050102
|
0 |
6
|
0 |
0 |
0 |
6
|
IL2RG
|
0 |
6
|
0 |
0 |
0 |
6
|
PEX10
|
0 |
6
|
0 |
0 |
0 |
6
|
PHYH
|
0 |
6
|
0 |
0 |
0 |
6
|
PPT1
|
3
|
3
|
0 |
0 |
0 |
6
|
TTPA
|
3
|
3
|
0 |
0 |
0 |
6
|
BLM
|
2
|
3
|
0 |
0 |
0 |
5
|
CDKN2A, LOC130001603
|
0 |
0 |
3
|
1
|
1
|
5
|
HBB, LOC107133510, LOC110006319
|
4
|
1
|
0 |
0 |
0 |
5
|
SLC26A2
|
3
|
2
|
0 |
0 |
0 |
5
|
BBS10
|
1
|
0 |
3
|
0 |
0 |
4
|
CDK4, TSPAN31
|
0 |
0 |
3
|
0 |
1
|
4
|
ERCC6, ERCC6-PGBD3
|
0 |
4
|
0 |
0 |
0 |
4
|
ERCC6, LOC126860933
|
0 |
4
|
0 |
0 |
0 |
4
|
GCDH, LOC117125594
|
0 |
4
|
0 |
0 |
0 |
4
|
GLA, RPL36A-HNRNPH2
|
0 |
4
|
0 |
0 |
0 |
4
|
HOGA1
|
2
|
0 |
2
|
0 |
0 |
4
|
IDUA, SLC26A1
|
1
|
3
|
0 |
0 |
0 |
4
|
LAMA2, LOC123864065
|
0 |
4
|
0 |
0 |
0 |
4
|
LOC123956210, SLC26A4
|
1
|
2
|
1
|
0 |
0 |
4
|
SGCG
|
0 |
3
|
1
|
0 |
0 |
4
|
SLC37A4
|
2
|
2
|
0 |
0 |
0 |
4
|
ADA, LOC107303343
|
0 |
3
|
0 |
0 |
0 |
3
|
AXDND1, NPHS2
|
2
|
1
|
0 |
0 |
0 |
3
|
GALT, LOC130001683
|
0 |
2
|
1
|
0 |
0 |
3
|
IDS
|
0 |
3
|
0 |
0 |
0 |
3
|
LOC126861339, SDHD
|
3
|
0 |
0 |
0 |
0 |
3
|
LOC126861615, PAH
|
2
|
1
|
0 |
0 |
0 |
3
|
LOC129391064, MAN2B1
|
0 |
3
|
0 |
0 |
0 |
3
|
LOC130061310, RAD51C
|
0 |
3
|
0 |
0 |
0 |
3
|
MEFV
|
2
|
1
|
0 |
0 |
0 |
3
|
MMAB
|
3
|
0 |
0 |
0 |
0 |
3
|
SERPINA1
|
1
|
1
|
1
|
0 |
0 |
3
|
SGCB
|
1
|
2
|
0 |
0 |
0 |
3
|
XPC
|
1
|
1
|
1
|
0 |
0 |
3
|
ACADVL, DVL2
|
0 |
2
|
0 |
0 |
0 |
2
|
AGA
|
1
|
1
|
0 |
0 |
0 |
2
|
ALMS1, LOC126806252
|
0 |
2
|
0 |
0 |
0 |
2
|
APBB1, SMPD1
|
2
|
0 |
0 |
0 |
0 |
2
|
BCHE
|
0 |
1
|
1
|
0 |
0 |
2
|
CLN5
|
1
|
1
|
0 |
0 |
0 |
2
|
CLN8
|
0 |
0 |
2
|
0 |
0 |
2
|
CLRN1
|
1
|
0 |
1
|
0 |
0 |
2
|
CPT2, LOC129930561
|
0 |
2
|
0 |
0 |
0 |
2
|
CYP21A2, LOC106780800, TNXB
|
2
|
0 |
0 |
0 |
0 |
2
|
FANCA, LOC112486223
|
2
|
0 |
0 |
0 |
0 |
2
|
FANCA, LOC132090450
|
1
|
0 |
1
|
0 |
0 |
2
|
FANCA, ZNF276
|
1
|
0 |
1
|
0 |
0 |
2
|
GBA1
|
2
|
0 |
0 |
0 |
0 |
2
|
GCDH, LOC126862860, SYCE2
|
2
|
0 |
0 |
0 |
0 |
2
|
GNPTG, LOC130058158
|
0 |
2
|
0 |
0 |
0 |
2
|
HFE
|
2
|
0 |
0 |
0 |
0 |
2
|
LAMA3
|
1
|
1
|
0 |
0 |
0 |
2
|
LOC111413029, TAT
|
0 |
2
|
0 |
0 |
0 |
2
|
LOC125446261, MLC1
|
0 |
1
|
1
|
0 |
0 |
2
|
LOC126862264, MEFV
|
2
|
0 |
0 |
0 |
0 |
2
|
LOC129929542, SDHB
|
2
|
0 |
0 |
0 |
0 |
2
|
LOC130063648, MAN2B1
|
0 |
2
|
0 |
0 |
0 |
2
|
NR2E3
|
2
|
0 |
0 |
0 |
0 |
2
|
PEX12
|
2
|
0 |
0 |
0 |
0 |
2
|
PROP1
|
2
|
0 |
0 |
0 |
0 |
2
|
ABCC8, LOC110121471
|
0 |
1
|
0 |
0 |
0 |
1
|
ACYP1, NPC2
|
0 |
0 |
1
|
0 |
0 |
1
|
AMT
|
1
|
0 |
0 |
0 |
0 |
1
|
AMT, NICN1
|
0 |
0 |
1
|
0 |
0 |
1
|
ARG1
|
0 |
1
|
0 |
0 |
0 |
1
|
BAP1, DNAH1
|
1
|
0 |
0 |
0 |
0 |
1
|
CAPN3, LOC130056921
|
0 |
1
|
0 |
0 |
0 |
1
|
CARD14, SGSH
|
1
|
0 |
0 |
0 |
0 |
1
|
CCDC107, RMRP
|
1
|
0 |
0 |
0 |
0 |
1
|
CDK4, LOC130008148
|
0 |
0 |
1
|
0 |
0 |
1
|
CDKL5, RS1
|
1
|
0 |
0 |
0 |
0 |
1
|
CFTR, LOC113633877
|
1
|
0 |
0 |
0 |
0 |
1
|
CFTR, LOC113664106
|
1
|
0 |
0 |
0 |
0 |
1
|
DHDDS
|
1
|
0 |
0 |
0 |
0 |
1
|
DNAH5, LOC107457585
|
0 |
1
|
0 |
0 |
0 |
1
|
EGFR
|
0 |
1
|
0 |
0 |
0 |
1
|
ERCC8, NDUFAF2
|
1
|
0 |
0 |
0 |
0 |
1
|
FANCA, LOC130059837
|
0 |
1
|
0 |
0 |
0 |
1
|
FKRP
|
1
|
0 |
0 |
0 |
0 |
1
|
GBE1
|
1
|
0 |
0 |
0 |
0 |
1
|
HBA1, HBA2, LOC106804612
|
1
|
0 |
0 |
0 |
0 |
1
|
HBB, LOC106099062, LOC107133510, LOC110006319
|
1
|
0 |
0 |
0 |
0 |
1
|
HOXB13
|
0 |
0 |
0 |
0 |
1
|
1
|
HSD17B4, LOC129994460
|
0 |
1
|
0 |
0 |
0 |
1
|
HYLS1, PUS3
|
1
|
0 |
0 |
0 |
0 |
1
|
LOC126806373, NEB
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC126860438, NBN
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC126862097, SLC12A6
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC129930446, MMACHC
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC129992585, SGCB
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC129998796, PEX1
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC130009366, SACS
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC130060903, NAGLU
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC130063376, MCOLN1
|
0 |
1
|
0 |
0 |
0 |
1
|
LOC132089454, SLC17A5
|
0 |
1
|
0 |
0 |
0 |
1
|
MET
|
0 |
1
|
0 |
0 |
0 |
1
|
MIR6753, TCIRG1
|
0 |
1
|
0 |
0 |
0 |
1
|
MTHFR
|
1
|
0 |
0 |
0 |
0 |
1
|
OPA3
|
1
|
0 |
0 |
0 |
0 |
1
|
PEX2
|
1
|
0 |
0 |
0 |
0 |
1
|
PTS
|
0 |
1
|
0 |
0 |
0 |
1
|
RS1
|
0 |
1
|
0 |
0 |
0 |
1
|
SGCD
|
0 |
1
|
0 |
0 |
0 |
1
|
SGSH, SLC26A11
|
1
|
0 |
0 |
0 |
0 |
1
|
TMEM216
|
1
|
0 |
0 |
0 |
0 |
1
|
XPA
|
1
|
0 |
0 |
0 |
0 |
1
|
Condition and significance breakdown #
Condition |
pathogenic |
likely pathogenic |
uncertain significance |
likely benign |
benign |
total |
Familial cancer of breast
|
2810
|
645
|
245
|
1058
|
1958
|
6716
|
Familial adenomatous polyposis 1
|
1237
|
82
|
159
|
257
|
1844
|
3579
|
Lynch syndrome 5
|
878
|
107
|
100
|
67
|
70
|
1222
|
Lynch syndrome 1
|
698
|
185
|
59
|
69
|
44
|
1055
|
Colorectal cancer, hereditary nonpolyposis, type 2
|
628
|
149
|
30
|
56
|
41
|
904
|
Lynch syndrome 4
|
298
|
103
|
70
|
18
|
24
|
513
|
Li-Fraumeni syndrome 1
|
156
|
253
|
40
|
5
|
13
|
467
|
Hereditary diffuse gastric adenocarcinoma
|
262
|
78
|
87
|
17
|
19
|
463
|
Cowden syndrome 1
|
297
|
117
|
12
|
10
|
7
|
443
|
Oligodontia-cancer predisposition syndrome
|
38
|
4
|
0 |
34
|
240
|
316
|
Breast-ovarian cancer, familial, susceptibility to, 2
|
190
|
9
|
0 |
66
|
13
|
278
|
Familial adenomatous polyposis 4
|
207
|
52
|
0 |
2
|
2
|
263
|
Nemaline myopathy 2
|
3
|
200
|
1
|
0 |
0 |
204
|
Primary ciliary dyskinesia 3
|
1
|
190
|
0 |
0 |
0 |
191
|
Breast-ovarian cancer, familial, susceptibility to, 3
|
93
|
60
|
13
|
15
|
9
|
190
|
Breast-ovarian cancer, familial, susceptibility to, 1
|
78
|
21
|
2
|
52
|
12
|
165
|
Merosin deficient congenital muscular dystrophy; Muscular dystrophy, limb-girdle, autosomal recessive 23
|
1
|
161
|
3
|
0 |
0 |
165
|
Breast-ovarian cancer, familial, susceptibility to, 4
|
75
|
47
|
22
|
10
|
9
|
163
|
Autosomal recessive Alport syndrome
|
1
|
150
|
5
|
0 |
0 |
156
|
Cystic fibrosis
|
77
|
72
|
0 |
0 |
0 |
149
|
Peutz-Jeghers syndrome
|
32
|
11
|
46
|
21
|
31
|
141
|
Paragangliomas 5
|
65
|
27
|
30
|
9
|
2
|
133
|
Polycystic kidney disease 4
|
1
|
116
|
2
|
0 |
0 |
119
|
Juvenile polyposis syndrome
|
56
|
14
|
18
|
11
|
6
|
105
|
Hereditary spastic paraplegia 15
|
0 |
99
|
1
|
0 |
0 |
100
|
Miyoshi muscular dystrophy 1; Autosomal recessive limb-girdle muscular dystrophy type 2B; Distal myopathy with anterior tibial onset
|
2
|
92
|
3
|
0 |
0 |
97
|
Usher syndrome type 2A
|
7
|
72
|
17
|
0 |
0 |
96
|
Ellis-van Creveld syndrome
|
1
|
91
|
1
|
0 |
0 |
93
|
Usher syndrome type 1
|
1
|
85
|
7
|
0 |
0 |
93
|
Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome
|
37
|
11
|
15
|
8
|
8
|
79
|
Familial adenomatous polyposis 3
|
65
|
12
|
0 |
1
|
0 |
78
|
Multiple endocrine neoplasia type 2A
|
19
|
5
|
30
|
14
|
9
|
77
|
Glycogen storage disease type III
|
2
|
73
|
0 |
0 |
0 |
75
|
X-linked Alport syndrome
|
0 |
70
|
0 |
0 |
0 |
70
|
Congenital hyperammonemia, type I
|
0 |
64
|
2
|
0 |
0 |
66
|
Junctional epidermolysis bullosa gravis of Herlitz
|
4
|
62
|
0 |
0 |
0 |
66
|
Cockayne syndrome type 2
|
0 |
65
|
0 |
0 |
0 |
65
|
Hereditary leiomyomatosis and renal cell cancer
|
34
|
30
|
0 |
1
|
0 |
65
|
Mucolipidosis type II; Pseudo-Hurler polydystrophy
|
1
|
64
|
0 |
0 |
0 |
65
|
Wilson disease
|
8
|
49
|
7
|
0 |
0 |
64
|
Non-ketotic hyperglycinemia
|
2
|
56
|
4
|
0 |
0 |
62
|
Becker muscular dystrophy; Duchenne muscular dystrophy
|
0 |
61
|
0 |
0 |
0 |
61
|
Menkes kinky-hair syndrome; Cutis laxa, X-linked; X-linked distal spinal muscular atrophy type 3
|
0 |
61
|
0 |
0 |
0 |
61
|
Birt-Hogg-Dube syndrome
|
44
|
11
|
0 |
2
|
3
|
60
|
Niemann-Pick disease, type C1
|
3
|
54
|
3
|
0 |
0 |
60
|
Alstrom syndrome
|
0 |
58
|
0 |
0 |
0 |
58
|
BAP1-related tumor predisposition syndrome
|
43
|
10
|
0 |
4
|
1
|
58
|
Maple syrup urine disease
|
3
|
50
|
2
|
0 |
0 |
55
|
Congenital lactic acidosis, Saguenay-Lac-Saint-Jean type
|
0 |
54
|
0 |
0 |
0 |
54
|
Deficiency of alpha-mannosidase
|
2
|
51
|
0 |
0 |
0 |
53
|
Peroxisome biogenesis disorder 1A (Zellweger); Peroxisome biogenesis disorder 1B
|
0 |
51
|
1
|
0 |
0 |
52
|
Paragangliomas 4
|
29
|
14
|
5
|
0 |
1
|
49
|
Abetalipoproteinaemia
|
0 |
48
|
0 |
0 |
0 |
48
|
Familial dysautonomia
|
1
|
47
|
0 |
0 |
0 |
48
|
Melanoma-pancreatic cancer syndrome
|
5
|
10
|
19
|
6
|
8
|
48
|
Usher syndrome type 1D
|
1
|
41
|
5
|
0 |
0 |
47
|
Pendred syndrome
|
12
|
24
|
10
|
0 |
0 |
46
|
Phenylketonuria
|
21
|
23
|
0 |
0 |
0 |
44
|
Fanconi anemia complementation group A
|
5
|
35
|
3
|
0 |
0 |
43
|
Finnish congenital nephrotic syndrome
|
3
|
34
|
5
|
0 |
0 |
42
|
Hyperinsulinemic hypoglycemia, familial, 1
|
2
|
33
|
7
|
0 |
0 |
42
|
Holocarboxylase synthetase deficiency
|
0 |
39
|
1
|
0 |
0 |
40
|
Tay-Sachs disease
|
8
|
30
|
2
|
0 |
0 |
40
|
Multiple endocrine neoplasia, type 1
|
17
|
6
|
6
|
5
|
4
|
38
|
Pyruvate carboxylase deficiency
|
0 |
38
|
0 |
0 |
0 |
38
|
Bardet-Biedl syndrome 2
|
2
|
30
|
3
|
0 |
0 |
35
|
Hermansky-Pudlak syndrome 3
|
1
|
34
|
0 |
0 |
0 |
35
|
Junctional epidermolysis bullosa gravis of Herlitz; Junctional epidermolysis bullosa, non-Herlitz type
|
2
|
32
|
0 |
0 |
0 |
34
|
Agenesis of the corpus callosum with peripheral neuropathy
|
2
|
31
|
0 |
0 |
0 |
33
|
Cohen syndrome
|
2
|
29
|
2
|
0 |
0 |
33
|
Deficiency of UDPglucose-hexose-1-phosphate uridylyltransferase
|
5
|
26
|
2
|
0 |
0 |
33
|
Congenital amegakaryocytic thrombocytopenia
|
1
|
31
|
0 |
0 |
0 |
32
|
Glycogen storage disease, type II
|
5
|
24
|
3
|
0 |
0 |
32
|
Propionic acidemia
|
1
|
29
|
1
|
0 |
0 |
31
|
Tuberous sclerosis 2
|
7
|
6
|
0 |
9
|
9
|
31
|
Very long chain acyl-CoA dehydrogenase deficiency
|
3
|
18
|
10
|
0 |
0 |
31
|
Von Hippel-Lindau syndrome
|
20
|
9
|
0 |
1
|
0 |
30
|
Charlevoix-Saguenay spastic ataxia
|
2
|
25
|
1
|
0 |
0 |
28
|
Methylmalonic aciduria due to methylmalonyl-CoA mutase deficiency
|
0 |
27
|
1
|
0 |
0 |
28
|
Paragangliomas 3
|
14
|
9
|
4
|
1
|
0 |
28
|
Bifunctional peroxisomal enzyme deficiency; Perrault syndrome 1
|
0 |
25
|
2
|
0 |
0 |
27
|
Tuberous sclerosis 1
|
14
|
7
|
0 |
4
|
2
|
27
|
beta Thalassemia
|
21
|
6
|
0 |
0 |
0 |
27
|
Sandhoff disease
|
1
|
25
|
0 |
0 |
0 |
26
|
Argininosuccinate lyase deficiency
|
4
|
20
|
1
|
0 |
0 |
25
|
Mucopolysaccharidosis, MPS-I-H/S
|
1
|
24
|
0 |
0 |
0 |
25
|
Mucopolysaccharidosis, MPS-III-C
|
3
|
19
|
3
|
0 |
0 |
25
|
Autosomal recessive congenital ichthyosis 1
|
3
|
19
|
2
|
0 |
0 |
24
|
Autosomal recessive nonsyndromic hearing loss 77
|
0 |
23
|
1
|
0 |
0 |
24
|
Smith-Lemli-Opitz syndrome
|
7
|
17
|
0 |
0 |
0 |
24
|
Glycogen storage disease, type VII
|
1
|
22
|
0 |
0 |
0 |
23
|
PMM2-congenital disorder of glycosylation
|
8
|
14
|
1
|
0 |
0 |
23
|
Severe X-linked myotubular myopathy
|
0 |
23
|
0 |
0 |
0 |
23
|
Autosomal recessive limb-girdle muscular dystrophy type 2A
|
3
|
17
|
2
|
0 |
0 |
22
|
Autosomal recessive nonsyndromic hearing loss 1A
|
15
|
1
|
6
|
0 |
0 |
22
|
Classic homocystinuria
|
4
|
16
|
2
|
0 |
0 |
22
|
Ehlers-Danlos syndrome, dermatosparaxis type
|
1
|
21
|
0 |
0 |
0 |
22
|
Mitochondrial trifunctional protein deficiency; Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency
|
0 |
22
|
0 |
0 |
0 |
22
|
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A3
|
2
|
19
|
1
|
0 |
0 |
22
|
Cholestanol storage disease
|
4
|
17
|
0 |
0 |
0 |
21
|
Fanconi anemia complementation group C
|
3
|
18
|
0 |
0 |
0 |
21
|
Galactosylceramide beta-galactosidase deficiency
|
4
|
16
|
1
|
0 |
0 |
21
|
GNE myopathy
|
5
|
15
|
0 |
0 |
0 |
20
|
Peroxisome biogenesis disorder 4A (Zellweger)
|
0 |
20
|
0 |
0 |
0 |
20
|
Primary hyperoxaluria, type I
|
3
|
16
|
1
|
0 |
0 |
20
|
Pyruvate dehydrogenase E3 deficiency
|
2
|
18
|
0 |
0 |
0 |
20
|
Colorectal cancer, susceptibility to, 10
|
0 |
3
|
7
|
8
|
1
|
19
|
Colorectal cancer, susceptibility to, 12
|
0 |
0 |
15
|
3
|
1
|
19
|
Microcephaly, normal intelligence and immunodeficiency
|
0 |
19
|
0 |
0 |
0 |
19
|
Bardet-Biedl syndrome 1
|
1
|
15
|
2
|
0 |
0 |
18
|
Bardet-Biedl syndrome 13; Meckel syndrome, type 1; Joubert syndrome 28
|
0 |
18
|
0 |
0 |
0 |
18
|
Megalencephalic leukoencephalopathy with subcortical cysts 1
|
1
|
16
|
1
|
0 |
0 |
18
|
Neuronal ceroid lipofuscinosis 2
|
3
|
15
|
0 |
0 |
0 |
18
|
Polyglandular autoimmune syndrome, type 1
|
3
|
15
|
0 |
0 |
0 |
18
|
Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-negative, due to adenosine deaminase deficiency
|
1
|
17
|
0 |
0 |
0 |
18
|
Sjögren-Larsson syndrome
|
1
|
17
|
0 |
0 |
0 |
18
|
Usher syndrome type 1C
|
2
|
14
|
2
|
0 |
0 |
18
|
Deficiency of galactokinase
|
0 |
16
|
1
|
0 |
0 |
17
|
Achromatopsia 3
|
0 |
14
|
2
|
0 |
0 |
16
|
Carnitine palmitoyl transferase 1A deficiency
|
1
|
15
|
0 |
0 |
0 |
16
|
Congenital lipoid adrenal hyperplasia due to STAR deficency
|
1
|
15
|
0 |
0 |
0 |
16
|
Glutaric aciduria, type 1
|
4
|
11
|
1
|
0 |
0 |
16
|
Hereditary factor XI deficiency disease
|
0 |
14
|
2
|
0 |
0 |
16
|
Lysosomal acid lipase deficiency
|
2
|
14
|
0 |
0 |
0 |
16
|
ALG6-congenital disorder of glycosylation 1C
|
0 |
14
|
1
|
0 |
0 |
15
|
Deficiency of steroid 11-beta-monooxygenase
|
0 |
14
|
1
|
0 |
0 |
15
|
Familial adenomatous polyposis 2
|
7
|
7
|
0 |
1
|
0 |
15
|
GM1 gangliosidosis type 2; GM1 gangliosidosis type 3; Infantile GM1 gangliosidosis
|
0 |
15
|
0 |
0 |
0 |
15
|
Hereditary fructosuria
|
3
|
9
|
3
|
0 |
0 |
15
|
Medium-chain acyl-coenzyme A dehydrogenase deficiency
|
3
|
12
|
0 |
0 |
0 |
15
|
Rhizomelic chondrodysplasia punctata type 1
|
2
|
13
|
0 |
0 |
0 |
15
|
Autosomal recessive DOPA responsive dystonia
|
1
|
13
|
0 |
0 |
0 |
14
|
Isovaleryl-CoA dehydrogenase deficiency
|
1
|
12
|
1
|
0 |
0 |
14
|
Metachromatic leukodystrophy
|
6
|
8
|
0 |
0 |
0 |
14
|
Niemann-Pick disease, type C2
|
0 |
13
|
1
|
0 |
0 |
14
|
Pyknodysostosis
|
0 |
14
|
0 |
0 |
0 |
14
|
Tyrosinemia type I
|
5
|
9
|
0 |
0 |
0 |
14
|
Adult hypophosphatasia; Childhood hypophosphatasia; Infantile hypophosphatasia
|
2
|
10
|
1
|
0 |
0 |
13
|
Autosomal recessive osteopetrosis 1
|
1
|
11
|
1
|
0 |
0 |
13
|
Birt-Hogg-Dube syndrome 1
|
9
|
2
|
0 |
2
|
0 |
13
|
Cockayne syndrome type 1
|
2
|
11
|
0 |
0 |
0 |
13
|
Renal carnitine transport defect
|
2
|
9
|
2
|
0 |
0 |
13
|
Sialic acid storage disease, severe infantile type; Salla disease
|
0 |
13
|
0 |
0 |
0 |
13
|
Mucolipidosis type IV
|
1
|
11
|
0 |
0 |
0 |
12
|
Mucopolysaccharidosis, MPS-III-A
|
3
|
8
|
1
|
0 |
0 |
12
|
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4; Autosomal recessive limb-girdle muscular dystrophy type 2M; Muscular dystrophy-dystroglycanopathy (congenital without intellectual disability), type B4
|
0 |
12
|
0 |
0 |
0 |
12
|
Nephrotic syndrome, type 2
|
4
|
7
|
1
|
0 |
0 |
12
|
Niemann-Pick disease, type B; Niemann-Pick disease, type A
|
0 |
8
|
4
|
0 |
0 |
12
|
Primary hyperoxaluria, type II
|
1
|
11
|
0 |
0 |
0 |
12
|
Arginase deficiency
|
1
|
10
|
0 |
0 |
0 |
11
|
Citrullinemia type I
|
1
|
9
|
1
|
0 |
0 |
11
|
Glycogen storage disease due to glucose-6-phosphatase deficiency type IA
|
7
|
4
|
0 |
0 |
0 |
11
|
Melanoma, cutaneous malignant, susceptibility to, 3
|
0 |
0 |
6
|
1
|
4
|
11
|
Methylmalonic aciduria, cblA type
|
1
|
10
|
0 |
0 |
0 |
11
|
Paragangliomas 1
|
10
|
1
|
0 |
0 |
0 |
11
|
Biotinidase deficiency
|
6
|
2
|
2
|
0 |
0 |
10
|
Deficiency of butyryl-CoA dehydrogenase
|
1
|
9
|
0 |
0 |
0 |
10
|
Neuronal ceroid lipofuscinosis 3
|
0 |
7
|
3
|
0 |
0 |
10
|
Spongy degeneration of central nervous system
|
4
|
6
|
0 |
0 |
0 |
10
|
Alkaptonuria
|
0 |
9
|
0 |
0 |
0 |
9
|
Autosomal recessive limb-girdle muscular dystrophy type 2D
|
1
|
7
|
1
|
0 |
0 |
9
|
Deficiency of hydroxymethylglutaryl-CoA lyase
|
0 |
7
|
2
|
0 |
0 |
9
|
GNPTG-mucolipidosis
|
0 |
8
|
1
|
0 |
0 |
9
|
Gaucher disease type I
|
6
|
3
|
0 |
0 |
0 |
9
|
Mucopolysaccharidosis, MPS-II
|
0 |
9
|
0 |
0 |
0 |
9
|
Pili torti-deafness syndrome; GRACILE syndrome; Mitochondrial complex III deficiency nuclear type 1
|
0 |
7
|
2
|
0 |
0 |
9
|
Tyrosinemia type II
|
0 |
9
|
0 |
0 |
0 |
9
|
Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
|
8
|
0 |
0 |
0 |
0 |
8
|
Cobalamin C disease
|
1
|
6
|
1
|
0 |
0 |
8
|
Mucopolysaccharidosis, MPS-III-B
|
0 |
7
|
1
|
0 |
0 |
8
|
Adrenoleukodystrophy
|
0 |
6
|
1
|
0 |
0 |
7
|
Choroideremia
|
0 |
7
|
0 |
0 |
0 |
7
|
Ornithine carbamoyltransferase deficiency
|
0 |
7
|
0 |
0 |
0 |
7
|
Autosomal recessive polycystic kidney disease
|
6
|
0 |
0 |
0 |
0 |
6
|
Familial isolated deficiency of vitamin E
|
3
|
3
|
0 |
0 |
0 |
6
|
Neuronal ceroid lipofuscinosis 1
|
3
|
3
|
0 |
0 |
0 |
6
|
Peroxisome biogenesis disorder 6A (Zellweger); Peroxisome biogenesis disorder 6B
|
0 |
6
|
0 |
0 |
0 |
6
|
Phytanic acid storage disease
|
0 |
6
|
0 |
0 |
0 |
6
|
X-linked severe combined immunodeficiency
|
0 |
6
|
0 |
0 |
0 |
6
|
Bloom syndrome
|
2
|
3
|
0 |
0 |
0 |
5
|
Carnitine palmitoyl transferase II deficiency, severe infantile form; Carnitine palmitoyl transferase II deficiency, myopathic form; Carnitine palmitoyl transferase II deficiency, neonatal form
|
0 |
3
|
2
|
0 |
0 |
5
|
Familial Mediterranean fever
|
4
|
1
|
0 |
0 |
0 |
5
|
Ocular cystinosis; Juvenile nephropathic cystinosis; Nephropathic cystinosis
|
0 |
5
|
0 |
0 |
0 |
5
|
3MC syndrome 2
|
3
|
1
|
0 |
0 |
0 |
4
|
Achondrogenesis, type IB
|
3
|
1
|
0 |
0 |
0 |
4
|
Autosomal recessive limb-girdle muscular dystrophy type 2C
|
0 |
3
|
1
|
0 |
0 |
4
|
Autosomal recessive limb-girdle muscular dystrophy type 2E
|
1
|
3
|
0 |
0 |
0 |
4
|
Bardet-Biedl syndrome 10
|
1
|
0 |
3
|
0 |
0 |
4
|
Ceroid lipofuscinosis, neuronal, 6A; Ceroid lipofuscinosis, neuronal, 6B (Kufs type)
|
1
|
3
|
0 |
0 |
0 |
4
|
Diastrophic dysplasia
|
3
|
1
|
0 |
0 |
0 |
4
|
Fabry disease
|
0 |
4
|
0 |
0 |
0 |
4
|
Glucose-6-phosphate transport defect
|
2
|
2
|
0 |
0 |
0 |
4
|
Multiple epiphyseal dysplasia type 4
|
3
|
1
|
0 |
0 |
0 |
4
|
Niemann-Pick disease, type A
|
4
|
0 |
0 |
0 |
0 |
4
|
Primary hyperoxaluria type 3
|
2
|
0 |
2
|
0 |
0 |
4
|
Alpha-1-antitrypsin deficiency
|
1
|
1
|
1
|
0 |
0 |
3
|
Carnitine palmitoyl transferase II deficiency, severe infantile form
|
3
|
0 |
0 |
0 |
0 |
3
|
Ceroid lipofuscinosis, neuronal, 6A; Adult neuronal ceroid lipofuscinosis
|
0 |
3
|
0 |
0 |
0 |
3
|
Infantile hypophosphatasia
|
2
|
1
|
0 |
0 |
0 |
3
|
Methylmalonic aciduria, cblB type
|
3
|
0 |
0 |
0 |
0 |
3
|
Xeroderma pigmentosum, group C
|
1
|
1
|
1
|
0 |
0 |
3
|
Aspartylglucosaminuria
|
1
|
1
|
0 |
0 |
0 |
2
|
Bifunctional peroxisomal enzyme deficiency
|
0 |
2
|
0 |
0 |
0 |
2
|
Deficiency of butyrylcholinesterase
|
0 |
1
|
1
|
0 |
0 |
2
|
GRACILE syndrome
|
2
|
0 |
0 |
0 |
0 |
2
|
Hemochromatosis type 1
|
2
|
0 |
0 |
0 |
0 |
2
|
Hurler syndrome
|
2
|
0 |
0 |
0 |
0 |
2
|
Juvenile retinoschisis
|
1
|
1
|
0 |
0 |
0 |
2
|
Nephropathic cystinosis
|
1
|
1
|
0 |
0 |
0 |
2
|
Neuronal ceroid lipofuscinosis 5
|
1
|
1
|
0 |
0 |
0 |
2
|
Neuronal ceroid lipofuscinosis 8
|
0 |
0 |
2
|
0 |
0 |
2
|
Peroxisome biogenesis disorder 1A (Zellweger)
|
2
|
0 |
0 |
0 |
0 |
2
|
Peroxisome biogenesis disorder 3A (Zellweger)
|
2
|
0 |
0 |
0 |
0 |
2
|
Pituitary hormone deficiency, combined, 2
|
2
|
0 |
0 |
0 |
0 |
2
|
3-Methylglutaconic aciduria type 3
|
1
|
0 |
0 |
0 |
0 |
1
|
6-Pyruvoyl-tetrahydrobiopterin synthase deficiency
|
0 |
1
|
0 |
0 |
0 |
1
|
Achondrogenesis, type IB; Atelosteogenesis type II; Diastrophic dysplasia
|
0 |
1
|
0 |
0 |
0 |
1
|
Autosomal recessive limb-girdle muscular dystrophy type 2F
|
0 |
1
|
0 |
0 |
0 |
1
|
Autosomal recessive limb-girdle muscular dystrophy type 2I
|
1
|
0 |
0 |
0 |
0 |
1
|
Enhanced S-cone syndrome
|
1
|
0 |
0 |
0 |
0 |
1
|
Enhanced S-cone syndrome; Retinitis pigmentosa 37
|
1
|
0 |
0 |
0 |
0 |
1
|
Glycogen storage disease, type IV
|
1
|
0 |
0 |
0 |
0 |
1
|
Homocystinuria due to methylene tetrahydrofolate reductase deficiency
|
1
|
0 |
0 |
0 |
0 |
1
|
Hydrolethalus syndrome 1
|
1
|
0 |
0 |
0 |
0 |
1
|
Joubert syndrome 2
|
1
|
0 |
0 |
0 |
0 |
1
|
Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency
|
1
|
0 |
0 |
0 |
0 |
1
|
Lung cancer
|
0 |
1
|
0 |
0 |
0 |
1
|
Meckel syndrome, type 1
|
1
|
0 |
0 |
0 |
0 |
1
|
Metaphyseal chondrodysplasia, McKusick type
|
1
|
0 |
0 |
0 |
0 |
1
|
Multiple endocrine neoplasia type 2B
|
1
|
0 |
0 |
0 |
0 |
1
|
Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4
|
1
|
0 |
0 |
0 |
0 |
1
|
Muscular dystrophy-dystroglycanopathy (congenital with intellectual disability), type B3
|
1
|
0 |
0 |
0 |
0 |
1
|
Papillary renal cell carcinoma type 1
|
0 |
1
|
0 |
0 |
0 |
1
|
Peroxisome biogenesis disorder 1B
|
1
|
0 |
0 |
0 |
0 |
1
|
Peroxisome biogenesis disorder 5A (Zellweger)
|
1
|
0 |
0 |
0 |
0 |
1
|
Peroxisome biogenesis disorder type 3B
|
1
|
0 |
0 |
0 |
0 |
1
|
Prostate cancer, hereditary, 9
|
0 |
0 |
0 |
0 |
1
|
1
|
Pseudo-Hurler polydystrophy
|
1
|
0 |
0 |
0 |
0 |
1
|
Retinitis pigmentosa 59
|
1
|
0 |
0 |
0 |
0 |
1
|
Salla disease
|
1
|
0 |
0 |
0 |
0 |
1
|
Usher syndrome type 3
|
1
|
0 |
0 |
0 |
0 |
1
|
Usher syndrome type 3A
|
0 |
0 |
1
|
0 |
0 |
1
|
Xeroderma pigmentosum group A
|
1
|
0 |
0 |
0 |
0 |
1
|
alpha Thalassemia
|
1
|
0 |
0 |
0 |
0 |
1
|
The information on this website is not intended for direct
diagnostic use or medical decision-making without review by a
genetics professional. Individuals should not change their
health behavior solely on the basis of information contained on
this website. Neither the University of Utah nor the National
Institutes of Health independently verfies the submitted
information. If you have questions about the information
contained on this website, please see a health care
professional.